The combination of cetuximab (CTX) and chemotherapy, such as FOLFOX or FOLFIRI, is currently the standard treatment for metastatic colorectal cancer (mCRC). Zoledronic acid (ZOL) is used in patients with bone metastasis. We herein report our experience with the case of a 58-year-old male patient with metastatic rectal cancer who was treated with ZOL + CTX as third-line therapy, and in whom this combination appeared to be effective. Although the patient developed bone metastasis and cardiac tamponade due to the recurrence of rectal cancer, he survived for approximately 10 months after the initiation of ZOL and CTX treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482389 | PMC |
http://dx.doi.org/10.3892/mco.2019.1836 | DOI Listing |
Urology
January 2025
Department of Urology, Louisiana State University Health, Shreveport, LA USA. Electronic address:
Eur J Radiol
January 2025
Department of Radiology, Mayo Clinic Rochester. 200 First Street SW, Rochester, MN 55905, USA; Department of Radiology, University of Sao Paulo, R. Dr. Ovídio Pires de Campos, 75 - Cerqueira César, São Paulo, SP 05403-010, Brazil. Electronic address:
MRI plays a critical role in the local staging, restaging, surveillance, and risk stratification of patients, ensuring they receive the most tailored therapy. As such, radiologists must be familiar not only with the key MRI findings that influence management decisions but also with the appropriate MRI protocols and structured reporting. Given the complexity of selecting the optimal therapy for each patient-which often requires multidisciplinary discussions-radiologists should be well-versed in relevant treatment strategies and surgical terms, understanding their significance in guiding patient care.
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Division of Colorectal Surgery, Changzheng Hospital, Navy Medical University, Shanghai, China.
Zhonghua Bing Li Xue Za Zhi
February 2025
Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, U S A.
Int J Radiat Oncol Biol Phys
January 2025
The Royal Marsden NHS Foundation Trust, London SM2 5PT, UK; Radiotherapy and Imaging Division, Institute of Cancer Research, London SM2 5NG, UK.
Purpose: In the PACE-B study, a non-randomised comparison of toxicity outcomes between stereotactic body radiotherapy (SBRT) platforms revealed fewer urinary side-effects with CyberKnife (CK) compared to conventional linac (CL) SBRT. This analysis compares baseline characteristics and planning dosimetry between the CK-SBRT and CL-SBRT cohorts in PACE-B, aiming to provide insight into possible reasons for differing toxicity outcomes between the platforms.
Methods: Dosimetric parameters for the surrogate urethra (SU), contoured urethra, bladder, bladder trigone (BT), and rectum were extracted from available CT planning scans of PACE-B SBRT patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!